Table 1. Correlations between clinicopathological factors and Tertiary Lymphoid Structures (TLS).
| n or median | TLS | ||||
|---|---|---|---|---|---|
| low | high | p | |||
| Age | <75 years | 12 | 6 | 6 | 1.0 |
| ≥75 years | 7 | 4 | 3 | ||
| Gender | Female | 7 | 2 | 5 | 0.350 |
| Male | 12 | 8 | 4 | ||
| Performance status | 0 | 5 | 3 | 2 | 0.794 |
| 1 | 9 | 4 | 5 | ||
| 2 | 5 | 3 | 2 | ||
| Histology | Differentiated | 6 | 3 | 3 | 1.0 |
| Undifferentiated | 13 | 7 | 6 | ||
| pT status | 2–3 | 6 | 4 | 3 | 1.0 |
| 4 | 13 | 6 | 6 | ||
| pN status | 0 | 3 | 2 | 1 | 1.0 |
| 1–3 | 16 | 8 | 8 | ||
| pStage | I-III | 11 | 5 | 6 | 0.650 |
| IV | 8 | 5 | 3 | ||
| The number of CD103+ T cells | 22.2 (10.2–42.2) | 18.7 (7.4–42.6) | 25.2 (18.3–39.9) | 0.191 | |
| Target for treatment | |||||
| Liver metastasis | 3 | 3 | 0 | ||
| Lymph node metastasis | 5 | 2 | 3 | 0.261 | |
| Peritoneum metastasis | 11 | 5 | 6 | ||
| Time from surgery to disease recurrence (month) | 9.2 (6.5–18.2) | 12.3 (6.6–32.6) | 9.0 (6.0–13.9) | 0.327 | |
| Time from initiation of 1st-line chemotherapy to nivolumab (month) | 14.7 (7.0–28.2) | 12.9 (6.4–29.2) | 18.0 (9.2–27.2) | 0.624 | |
| Nivolumab administration time (month) | 4.9 (1.9–9.3) | 3.9 (2.1–7.0) | 4.9 (1.6–9.7) | 0.683 | |
| irAE | - | 15 | 10 | 5 | 0.033 |
| + | 4 | 0 | 4 | ||
| Response to treatment | PR | 3 | 0 | 3 | 0.062 |
| SD | 5 | 2 | 3 | ||
| PD | 11 | 8 | 3 | ||
TLS; Tertiary lymphoid structure, irAE; Immune-related Adverse Event, PR; Partial Response, SD; Stable Disease, PD; Progressive Disease
Data are expressed as median range (interquartile range) or n.